Antisense oligonucleotides, short synthetic fragments of DNA or RNA, are gaining popularity due to their targeted treatment capabilities in a range of diseases. Leading companies in this field include Ionis Pharmaceuticals with over 40 antisense drugs in its pipeline, Isarna Therapeutics targeting TGF-β in key biological processes, Regulus Therapeutics focusing on microRNAs, Sarepta Therapeutics developing PPMO therapies, Secarna Pharmaceuticals working on therapies for immuno-oncology and fibrotic diseases, and Wave Life Sciences using its proprietary PRISM platform for the development of antisense therapeutics.
Dutch Ministry of Finance confirms incident, systems taken offline – Cyber Daily
Dutch Ministry of Finance confirms incident, systems taken offline Cyber Daily
